Navigation Links
Epizyme Receives Orphan Drug Designation for EPZ-5676
Date:8/16/2013

CAMBRIDGE, Mass., Aug. 16, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for EPZ-5676. Criteria for orphan drug designation requires that the product be intended for treatment of a rare disease or condition, classified as affecting fewer than 200,000 people in the United States.

Orphan drug designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include tax credits, research and development grant funding and reduced filing fees during development or at the time of application for marketing approval. Once approved, the product may qualify for seven years of marketing exclusivity independent of any other intellectual property.

About EPZ-5676

Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r). Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in the increased expression of genes causing leukemia.

In September 2012, Epizyme initiated a Phase 1 clinical trial for EPZ-5676. The company believes EPZ-5676 is the first HMTi to enter human clinical development. As of August 2013, this program is in the dose escalation phase and is expected to initiate an expansion phase in the second half of 2013 that wil
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. Epizyme to Present at Upcoming Conferences in February
3. Epizyme to Partner to Develop DOT1L Companion Diagnostic
4. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Epizyme, Inc. Announces Pricing of Initial Public Offering
6. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
7. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
8. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
9. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
10. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
11. Nephros Receives 510(k) Clearance for Hemodiafiltration System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... 2015 A global continuing medical ... and thyroid disorders in Latin America ... conference dedicated to these diseases.      (Logo: ... Manage Hypertension Online and Manage Thyroid ... EXCEMED - combine the world,s top expertise with ...
(Date:7/3/2015)... , July 3, 2015  Obsidian HDS, the ... an online service for the management of data on ... today that PharmaShine now includes the 2014 Open Payments ... Medicare Services on June 30. The data disclosed on ... transactions between industry and providers totaling $6.49 billion and ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved ... from Exenatide Taken Twice a Day, SAN FRANCISCO, ... Eli Lilly and Company (NYSE: LLY ), and ... a 52-week open-label clinical,study that showed the durable efficacy ...
... VIEW, Calif., June 9 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R),alprazolam) ... not meet its two,primary endpoints, which were the ... panic attack and the effect of AZ-002 on ...
Cached Medicine Technology:After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national president recruitment for Regional Care, ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the ... good blender and easily accessible, quality ingredients. Aurora Natural is proud to introduce a ... added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is offering a ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room ... Mariah N. Manzanares, MD as the new Medical Director of its Frisco facility. , ... of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:7/3/2015)... Alberta (PRWEB) , ... July 03, 2015 , ... Every ... their 24-Hour Train-a-Thon where they provide members of the Red Deer community with free ... full day of fitness training, games, food, events and entertainment raised thousands of charity ...
(Date:7/2/2015)... ... ... pleased to announce the opening of its newest location in Dallas, Texas. The opening is ... chain was listed as #22 on the Inc. 500 list of fastest growing companies in ... located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are excited ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Opens 18th Location in the Lone Star State 2
... guidelines for the treatment of exacerbations in cystic fibrosis ... clinical practices. "This is the first such comprehensive ... exacerbation of cystic fibrosis," said Susanna McColley, M.D., head ... the Cystic Fibrosis Center at Children,s Memorial Hospital and ...
... surprising reversal of long-standing scientific belief, researchers at the Mayo ... brain is not the trigger that leads to buildup of ... inflammation helps clear the brain of these noxious amyloid plaques ... mice that are predisposed to the disorder, say the researchers ...
... prescriptions issued by GPs has been caused by a year ... drugs on a long-term basis, according to researchers from the ... printed edition of British Medical Journal ( BMJ ... number of new patients diagnosed with depression over 11 years, ...
... discard stored embryos, studies show , THURSDAY, Oct. 22 ... playing a key role in many couples, decisions about ... using assisted reproductive technology or whether they will discard ... , Among the new findings, presented this week at ...
... exposing healthy kids to those already sick with the H1N1 flu ... are doing all they can to avoid the swine flu, some ... , These are parents who are reportedly arranging swine flu "parties" ... healthy children can be exposed to the virus through kids who ...
... worldwide study could one day lead to new treatments ... worldwide study has clinched the case that the gene ... involved in Parkinson,s disease. , "For those of us ... come up with insights that are applicable to more ...
Cached Medicine News:Health News:New clinical guidelines for exacerbations in cystic fibrosis 2Health News:Manipulating brain inflammation may help clear brain of amyloid plaques, Mayo Clinic researchers say 2Health News:Manipulating brain inflammation may help clear brain of amyloid plaques, Mayo Clinic researchers say 3Health News:Money Woes Keeping Many Couples From Fertility Treatments 2Health News:Money Woes Keeping Many Couples From Fertility Treatments 3Health News:Swine Flu Parties? Send Your Regrets, Experts Say 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 3
The Finntip 20 is suitable for applications requiring high precision and volumes of 0.2-20 ul. The tips are provided in convenient racks of 384 tips....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... is the gold standard for WBC ... with your technologists manual results- no ... RBC morphology advances cell separation to ... the differentiation of various disease states, ...
Medicine Products: